Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partially matched unrelated versus haploidentical donor hematopoietic cell transplantation in high‑risk AML/ALL/MDS
2015-005399-12Phase 3Completed
- Sponsor
- DKMS
- Start
- Dec 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of peripheral blood stem cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by DKMS. Primary endpoint: Overall survival. Started Dec 2016; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-005399-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005399-12.